CatS can degrade important host defense proteins such as lactoferrin, LL-37 and β-defensins and treatment with a CatS inhibitor in a transgenic mouse model with CF-like lung disease (βENaC-overexpressing mice) reduced lung inflammation, mucus obstruction and lung damage [64,65]. This evidence concerns the gene PIMREG and cystic fibrosis.